For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Astellas Paid 19.3 Billion Yen to Healthcare Professionals, 7.1 Billion Yen for Information Provisioning in FY2012
September 3, 2013
- Takeda’s OBLEAN Near-Certain to Debut as Japan’s 1st Anti-Obesity Drug in 20 Years
September 2, 2013
- Daiichi Sankyo Provided 36.6 Billion Yen to Physicians, Medical Institutions in FY2012, 22.7 Billion Yen for R&D
September 2, 2013
- US FDA Requests Additional Data for Tolvaptan for Treatment of ADPKD: Otsuka
September 2, 2013
- Orphan Drug Wholesaler S.D. Next to Swing into Black in FY2015 with Tailored Distribution Services: Pres.
August 30, 2013
- WHO Grants Prequalification to Eisai for Lymphatic Filariasis Treatment
August 30, 2013
- New Products Shake Up Market for Osteoporosis Treatments; Entry of Pralia Could Lead to Change in Market Structure
August 30, 2013
- AnGes MG’s CIN Therapeutic Vaccine Project Picked for Health Ministry’s Research Grants
August 29, 2013
- Merck Serono’s Northeast Asian Development Zeros in on 4 Cancer Types: R&D Site Head
August 29, 2013
- Eisai Launches Higher-Dose Aricept 23 mg Tablet in South Korea
August 29, 2013
- Shionogi Paid a Total of 10.2 Billion Yen to Healthcare Professionals, 1 Billion for Research Grants
August 28, 2013
- Takeda Initiates Overseas PIII Trial of Actos for Delaying the Onset of MCI Due to Alzheimer’s Disease
August 28, 2013
- Takeda to Appoint Mr Roger as CFO
August 28, 2013
- Livalo AG Skips NHI Price Listing Again, Sandoz Won’t Comment on Diovan AG
August 27, 2013
- Astellas Launches Tacrolimus Extended-Release Capsules Astagraf XL in US
August 27, 2013
- LEO Pharma Files NDA for Psoriasis Drug, Paving Way for Full Foray into Japan Market
August 27, 2013
- Announcement: Oncology Japan 2013 to Be Held on November 5, 6
August 27, 2013
- Affinity Gel Market to Triple in 2017: Fuji Chimera Research Institute
August 26, 2013
- Somatropin BS SC Injection Approved for Full Range of Indications with Additional Indications: Sandoz
August 26, 2013
- Plavix, Diovan Rank 1st, 3rd in Japan Ethical Drugs Sales in April-June: IMS Japan
August 26, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…